Attack Mounts on Drug Prices

Congress debates legislation for a Medicare drug benefit while the industry expresses concerns about import control, drug counterfeiting, and patent rights.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-09-02-2002

PTC Therapeutics Gains FDA Approval for AADC Deficiency Gene Therapy

EMA’s CHMP Gives Positive Opinion for Use of Lecanemab in Early Alzheimer’s Disease

J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer